DECEMBER 2008

Meabco's medical advisor has advised that the applications and protocols for clinical trials complementary to the phase I/II(toxicity) trials already performed in Denmark are being filed.

AUGUST 2008

The US Patent and Trademark Office grants patent on the use of BP-C1 as an anti cancer agent.

AUGUST 2008

Meabco A/S has received approval (by the participating centre) to initiate a placebo-controlled randomized Phase II/III trial for BP-C1 in breast cancer patients.

JUNE 2008

Meabco A/S initiates collaboration with the Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society to study further the mechanism of action of BP-C1.

MARCH 2008

Meabco A/S announces promising results from an open-label Phase I/II trials for BP-C1 in breast cancer.

JANUARY 2008

Meabco A/S secures yet another round of financing, enabling the company to complete Phase II/III trials for BP-C1 in breast cancer.

DECEMBER 2007

The European Patent office grants patent on the use of BP-C1 as an anti cancer agent.